Catalent Pharma Solutions is expanding its drug development and delivery capabilities with significant investments at its Schorndorf, Germany facility. The expansion includes the addition of R&D and commercial scale fluid bed technology, OptiMelt hot melt extrusion, and elevated cGMP compliance for handling of OEB class 3 customer products. 


“This expansion follows recent investments in OSDrC OPTIDOSE optimized controlled release dose delivery technology at our Winchester, KY site in the U.S., and Lyopan fast-dissolve lyophilized tablet technology, representing Catalent’s commitment to continue innovating and furthering it’s position as the industry’s leading global partner in oral drug delivery technologies,” said Dr. Ian Muir, president of Catalent’s Modified Release Technologies business.